Association Between Pioglitazone and Urothelial Bladder Cancer

Urology, 05/25/2012

The U.S. Food and Drug Administration and the European Medicines Agency have recently informed the public of a potential impact of pioglitazone (Actos) use on bladder cancer incidence. These recommendations are based on 2 recent large published cohort studies indicating a possible association between pioglitazone use and bladder cancer development.

Print Article Summary Cat 2 CME Report